Antengene Corporation Limited
HKEX:6996.HK
Overview | Financials
Company Name | Antengene Corporation Limited |
Symbol | 6996.HK |
Currency | HKD |
Price | 0.54 |
Market Cap | 339,760,855 |
Dividend Yield | 0% |
52-week-range | 0.5 - 2.25 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jay Mei M.D., Ph.D. |
Website | https://www.antengene.com |
An error occurred while fetching data.
About Antengene Corporation Limited
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with solid tumors; ATG-527 (Verdinexor) that has completed Phase I evaluation for chronic human viral infections; ATG-019, a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD